Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 earnings results
Rigel Pharmaceuticals, Inc. (RIGL) reported Q3 2026 results on Nov 5, 2026, 4:10:22 PM ET: GAAP EPS $0.65 vs. $0.96 expected (miss by 32.5%); revenue $80.89M vs. $80.10M expected (beat by 1.0%). Outlook: Full year 2026 total revenues of approximately $290 to $295 million.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | $0.65 | $0.96 | Miss by 32.5% |
| Revenue | $80.89M | $80.10M | Beat by 1.0% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 5, 2026, 4:10:22 PM ET. Nexqual published them 2 min 4 s after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 16.5% from $69.46M; GAAP diluted EPS was $0.65 vs. $1.46 (−55.5%).
Stock reaction
The results came out after the market closed. RIGL closed at $39.65 on November 6, 2026, down 13.3% from its $45.71 close on November 5, 2026 before the results. Latest: $42.71 as of 11:40 AM ET, −6.6% since the pre-release close.
Questions and answers
Did Rigel Pharmaceuticals, Inc. beat earnings expectations?
No. Rigel Pharmaceuticals, Inc. reported GAAP EPS of $0.65 against an average analyst estimate of $0.96 (miss by 32.5%), and revenue of $80.89M against $80.10M expected (beat by 1.0%).
What were Rigel Pharmaceuticals, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of $0.65 and revenue of $80.89M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 16.5% from $69.46M; GAAP diluted EPS was $0.65 vs. $1.46 (−55.5%).
When did Rigel Pharmaceuticals, Inc. report Q3 2026 earnings?
Nov 5, 2026, 4:10:22 PM ET, in an SEC 8-K filing (Item 2.02).
How did RIGL stock react to the earnings?
The results came out after the market closed. RIGL closed at $39.65 on November 6, 2026, down 13.3% from its $45.71 close on November 5, 2026 before the results. Latest: $42.71 as of 11:40 AM ET, −6.6% since the pre-release close.
What did Rigel Pharmaceuticals, Inc. say about its outlook?
Full year 2026 total revenues of approximately $290 to $295 million.
More on RIGL
RIGL stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 5, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:40 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt